Candel Therapeutics, INC Form 4 insider transactions

Paul Peter Tak, CEO of Candel Therapeutics, sold 21,704 shares of common stock on January 15, 2025, at a price of $7.225 per share to cover tax withholding obligations related to vesting restricted stock units.

Candel Therapeutics' Chief Medical Officer, William Garrett Nichols, sold 10,428 shares of common stock to cover tax obligations related to vesting restricted stock units.

Francesca Barone, Chief Scientific Officer of Candel Therapeutics, sold 13,673 shares of common stock to cover tax withholding obligations related to vesting restricted stock units.

Charles Schoch, Interim CFO of Candel Therapeutics, sold 9,971 shares of common stock to cover tax withholding obligations related to vesting restricted stock units.

Candel Therapeutics CEO Paul Peter Tak sold 21,172 shares of common stock on January 8, 2025, to cover tax withholding obligations related to the vesting of restricted stock units.

Seshu Tyagarajan, Chief Technology Officer of Candel Therapeutics, sold shares to cover tax withholding obligations related to vesting restricted stock units.

William Garrett Nichols, Chief Medical Officer of Candel Therapeutics, sold 10,799 shares of common stock to cover tax withholding obligations related to vesting restricted stock units.

A Candel Therapeutics director, Estuardo Aguilar-Cordova, and related parties, sold a significant number of shares in multiple transactions over two days.

A Candel Therapeutics director, Estuardo Aguilar-Cordova, and related trusts, sold and acquired shares in multiple transactions between December 20th and December 24th, 2024.

Director Paul B. Manning reports acquiring additional shares of Candel Therapeutics through a trust and an LLC, while also disclosing shares held jointly with a spouse.

A Candel Therapeutics director, Estuardo Aguilar-Cordova, sold 800,000 shares of company stock across multiple transactions in December 2024.

Director Estuardo Aguilar-Cordova sold 60,000 shares of Candel Therapeutics stock over three days, reducing his direct holdings.

Candel Therapeutics' Chief Technology Officer, Seshu Tyagarajan, sold 20,392 shares of common stock to cover tax obligations related to vesting restricted stock units.

Candel Therapeutics CEO, Paul Peter Tak, sold 48,847 shares of common stock to cover tax obligations related to vesting restricted stock units.

Candel Therapeutics' Chief Medical Officer, William Garrett Nichols, sold 13,935 shares of common stock to cover tax obligations related to vesting restricted stock units.

Francesca Barone, Chief Scientific Officer of Candel Therapeutics, sold 22,081 shares of common stock to cover tax obligations related to vesting restricted stock units.

A Candel Therapeutics director, Estuardo Aguilar-Cordova, sold 20,000 shares of company stock at $4.97 per share on November 25, 2024.

Candel Therapeutics CEO, Paul Peter Tak, exercised stock options to acquire 12,900 shares of common stock at a price of $1.55 per share.

Director Estuardo Aguilar-Cordova reports multiple sales of Candel Therapeutics (CADL) stock between November 6th and November 8th, 2024.

Estuardo Aguilar-Cordova, a director and 10% owner of Candel Therapeutics, Inc., executed multiple sales of company stock between October 30 and November 1, 2024.

Director Estuardo Aguilar-Cordova and related entities decrease their holdings in Candel Therapeutics through a series of transactions between October 24 and October 28, 2024.

Director Estuardo Aguilar-Cordova reports selling shares of Candel Therapeutics (CADL) in multiple transactions.

Director Estuardo Aguilar-Cordova and related entities report sales of Candel Therapeutics stock over three days in October.

Seshu Tyagarajan, Chief Technology Officer of Candel Therapeutics, sold shares to cover tax withholding obligations related to vesting restricted stock units.

Candel Therapeutics CEO Paul Peter Tak sold 22,528 shares of common stock on July 17, 2024, at a price of $6.4726 per share to cover tax withholding obligations related to the vesting of restricted stock units.

Charles Schoch, Interim CFO of Candel Therapeutics, sold shares to cover tax withholding obligations related to vesting restricted stock units.

William Garrett Nichols, Chief Medical Officer of Candel Therapeutics, sold 10,875 shares of common stock to cover tax withholding obligations related to vesting restricted stock units.

Francesca Barone, Chief Scientific Officer of Candel Therapeutics, sold 14,051 shares of common stock to cover tax withholding obligations related to the vesting of restricted stock units.

Seshu Tyagarajan, Chief Technology Officer of Candel Therapeutics, sold 13,330 shares of common stock to cover tax withholding obligations related to vesting restricted stock units.

Candel Therapeutics CEO Paul Peter Tak sold 20,293 shares of common stock on July 11, 2024, to cover tax withholding obligations related to the vesting of restricted stock units.